Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Koto-ku
Clinical trial register · Japan

Clinical Trials in Koto-ku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie12 Amgen7 Astellas Pharma Global Development, Inc.6 Bristol-Myers Squibb5 Novartis Pharmaceuticals5
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Koto-ku

68 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Pfizer
Phase 3
600
Sapporo, Akashi, Hidaka, Koto-ku, Niigata
2026-10-09
Recruiting
Daiichi Sankyo
Phase 1/2
220
Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka
2026-09-17
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
392
Chuo-ku, Koto-ku
2026-09-02
Recruiting
Genmab
Phase 1
112
Hirakata, Chuo Ku, Koto-Ku
2026-08-13
Recruiting
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
NCT07617337ALK Positive Non-small Cell Lung Cancer
DrugLorlatinib
Chugai Pharmaceutical
Phase 1
102
Nagoya, Kashiwa, Sakai, Nagaizumi-cho, Chuo-ku, Koto-Ku
2026-07-24
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Kashiwa, Koto Ku
2026-06-08
Recruiting
AbbVie
Phase 3
990
Kashiwa-shi, Matsuyama, Kobe, Kawasaki-shi, Osaka, Koto-ku
2026-05-22
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
DrugXNW27011
Astellas Pharma Global Development, Inc.
Phase 1/2
150
Kashiwa-shi, Chuo-ku, Koto-ku
2026-05-04
Recruiting
AbbVie
Phase 2/3
900
Koto-ku
2026-04-30
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
Nagoya, Kashiwa-shi, Chuo-ku, Koto-ku
2026-04-08
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Kobe, Shiwa-gun Yahaba-cho, Koto-ku, Toyoma, Fukuoka, Niigata
2026-03-26
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama
2026-03-09
Recruiting
AbbVie
Phase 1
127
Bunkyo Ku, Koto-ku
2026-02-27
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
Kashiwa-shi, Hirakata-shi, Chuo-ku, Koto-ku
2026-02-05
Recruiting
Pfizer
Phase 3
800
Nagoya, Chiba, Kashiwa, Yokohama, Hidaka, Kitaadachi-gun, Nagaizumi-cho, Koto-ku
2025-12-11
Active, closed
Novartis Pharmaceuticals
Phase 1
6
Nagoya, Kobe, Bunkyo Ku, Koto Ku
2025-11-26
Recruiting
Bristol-Myers Squibb
Phase 1
32
Yokohama, Sunto-gun, Chuo-ku, Koto-ku
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Kawasaki, Bunkyo-ku, Koto-ku, Toyoma
2025-09-30
Recruiting
AbbVie
Phase 1
135
Kashiwa-shi, Kumamoto, Mibu, Bunkyo-ku, Koto-ku
2025-08-07
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Kashiwa, Hirakata, Chuo-ku, Koto-ku
2025-08-01
Recruiting
AbbVie
Phase 2
377
Akashi-shi, Chuo-Ku, Koto-ku
2025-07-30
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
404
Hirakata, Koto-ku
2025-07-25
Recruiting
Pfizer
Phase 3
674
Kurume, Sendai, Niigata, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Osaka
2025-04-01
Recruiting
Bayer
Phase 1/2
450
Nagoya, Kashiwa, Sakai, Sunto, Chuo-ku, Koto-ku
2025-03-21
Recruiting
Eiji Shinozaki
Phase 1
48
Koto-ku
2025-03-13
Recruiting
AbbVie
Phase 1/2
252
Nagoya, Hirosaki, Yokohama, Kyoto, Niigata, Takatsuki, Chuo-Ku, Koto-ku
2025-03-06
Active, closed
Amgen
Phase 2
252
Kurume-shi, Sapporo, Yokohama, Niigata, Hirakata-shi, Osaka, Sunto-gun, Koto-ku
2025-02-26
Recruiting
Bayer
Phase 2
111
Nagoya, Kashiwa, Sapporo, Sakai, Chuo-ku, Koto-ku
2025-02-13
Recruiting
Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
NCT07190443Breast Cancer, Locoregional Recurrence, Abemaciclib, Endocrine Therapy
DrugAbemaciclib
Japanese Foundation for Cancer Research
Phase 3
290
Koto-ku
2025-02-07
Active, closed
AbbVie
Phase 1
21
Nagoya, Kashiwa-shi, Koto-ku
2025-01-16
Active, closed
Amgen
Phase 2
61
Nagoya, Kashiwa-shi, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2024-12-26
Active, closed
AbbVie
Phase 2
185
Nagoya, Kashiwa-shi, Sunto-gun, Chuo-Ku, Koto-ku
2024-12-13
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Koto-Ku, Chou-ku, Osaka
2024-08-31
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Koto-ku, Shinagawa-ku, Okayama, Tokyo
2024-05-20
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
31
Kashiwa-shi, Sendai, Niigata, Osaka, Osakasayama-shi, Sunto-gun, Chuo-ku, Koto-ku
2024-05-07
Recruiting
Daiichi Sankyo
Phase 1/2
680
Nagoya, Kashiwa, Matsuyama, Ōsaka-sayama, Nagaizumi-cho, Chuo-ku, Koto-ku, Saitama
2024-04-10
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Bayer
Phase 1
198
Yokohama, Koto-ku
2024-03-07
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
87
Nagoya, Kashiwa-shi, Kanazawa, Yokohama, Osaka, Hamamatsu, Bunkyo-ku, Koto-Ku
2023-12-06
Recruiting
AbbVie
Phase 1
325
Nagoya, Kashiwa-shi, Kyoto, Sunto-gun, Chuo-Ku, Koto-ku
2023-11-09
Recruiting
NRG Oncology
Phase 3
3,960
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2023-10-18
Active, closed
AbbVie
Phase 1
135
Kashiwa-shi, Kyoto, Chuo-ku, Koto-ku
2023-06-09
Active, closed
A Rollover Study of CC-122
NCT05688475Non-Hodgkin Lymphoma
DrugDexamethasone
Bristol-Myers Squibb
Phase 1
12
Koto-ku
2023-04-11
Active, closed
AbbVie
Phase 1
288
Kashiwa-shi, Matsuyama, Sapporo, Kyoto, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2022-12-05
Active, closed
Amgen
Phase 1
184
Kashiwa-shi, Koto-ku
2022-08-24
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Osaka, Bunkyo Ku, Koto Ku
2022-07-07
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Chiba, Ōsaka-sayama, Chūō, Koto-Ku
2022-06-30
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Nagoya, Kashiwa, Yokohama, Sakai, Suita, Chuo-ku, Koto-ku
2022-06-07
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Kashiwa-shi, Sapporo, Suita-shi, Tokushima, Koto-ku, Osaka
2022-05-03
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Nagoya, Kashiwa-shi, Okayama, Osakasayama-shi, Sunto-gun, Koto-ku, Wakayama
2021-12-01
Active, closed
AbbVie
Phase 1
520
Nagoya, Kashiwa-shi, Yokohama, Kyoto, Niigata, Chuo-ku, Koto-ku, Wakayama
2021-10-13
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Isehara-Shi, Kumamoto-Shi Chuo-Ku, Naha, Osaka-Shi Chuo-Ku, Shinden, Koto-Ku, Fukushima, Hiroshima
2021-08-27
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
32
Kashiwa-shi, Yokohama, Hamamatsu, Bunkyō-Ku, Koto-ku, Mitaka-shi, Shinjuku-Ku, Chūōku
2021-07-30
Recruiting
NRG Oncology
Phase 3
1,670
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2021-06-23
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Nagoya, Kashiwa, Osaka, Chuo Ku, Koto Ku
2021-02-24
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
40
Kashiwa-shi, Kobe, Yokohama, Ina, Osaka, Takatsuki-shi, Hidaka-shi, Koto-Ku
2021-01-13
Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
NCT04683250RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1/2
244
Kashiwa-shi, Sendai, Okayama, Hirakata-shi, Osaka, Shizuoka, Chuo-ku, Koto-ku
2020-12-16
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Nagoya, Kashiwa-shi, Kawasaki, Osaka, Chuo-ku, Koto-ku
2020-09-15
Recruiting
Eisai Inc.
Phase 1/2
182
Chuo-ku, Koto-ku
2020-08-06
Recruiting
Amgen
Phase 1
479
Kashiwa-shi, Yokohama, Koto-ku
2020-03-04
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Nagoya, Kashiwa-shi, Koto-ku
2019-12-17
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Nagoya, Kashiwa, Sapporo, Yokohama, Kashihara, Bunkyo-ku, Chuo-ku, Koto-ku
2019-03-15
Active, closed
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
DrugDato-DXd
Daiichi Sankyo Co., Ltd.
Phase 1
890
Nagoya, Koto-Ku, Shinagawa-Ku, Chūōku, Kashiwa
2018-01-31
Active, closed
Takara Bio Inc.
Phase 1
36
Nagoya, Chiba, Kashiwa, Yokohama, Osaka, Chūōku, Koto-Ku
2017-09-25
Active, closed
Eisai Co., Ltd.
Phase 1
140
Kashiwa, Sapporo, Nishinomiya, Yokohama, Hidaka, Bunkyo-ku, Chuo-ku, Koto-ku
2017-08-18
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Taxol
National Cancer Institute (NCI)
Phase 2/3
582
Tōon, Sapporo, Kagoshima, Koto-ku, Osaka, Saitama, Tokyo
2016-05-03
Active, closed
National Cancer Institute (NCI)
Phase 3
579
Shiwa-gun, Kagoshima, Koto-ku, Saitama, Tokyo
2016-03-28
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Nagoya, Fukuoka, Akashi, Koto Ku
2015-12-11
Rows per page Showing 1–68 of 68
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/koto-ku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 68 of those studies with a site in Koto-ku.

How many clinical trials are recruiting in Koto-ku?

36 of the 68 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 31 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Koto-ku), 68 studies
PhaseStudiesRecruitingShare
Phase 1291342.6%
Phase 1/2131019.1%
Phase 211416.2%
Phase 310714.7%
Phase 2/3324.4%
Phase 4202.9%

Most active sponsors

Lead sponsors with the most studies (Koto-ku)
Lead sponsorStudiesRecruiting
AbbVie127
Amgen72
Astellas Pharma Global Development, Inc.65
Bristol-Myers Squibb54
Novartis Pharmaceuticals50
Ono Pharmaceutical Co., Ltd.40
Bayer33
Pfizer32
Seagen, a wholly owned subsidiary of Pfizer31
Daiichi Sankyo22
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.